Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Nurix Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026. Open the filing →
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
FAQ
- What is Nurix Therapeutics, Inc.'s EBIT?
- Nurix Therapeutics, Inc. (NRIX) reported EBIT of -$94.2M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s EBIT changed year-over-year?
- Nurix Therapeutics, Inc.'s EBIT decreased by 95.0% year-over-year, from -$48.32M to -$94.2M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s EBIT has grown at a 24.8% compound annual growth rate (CAGR), from -$117.89M to -$285.67M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Nurix Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude